Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Open Label, Two Parallel Arms, Intervention Trial Comparing the Effect of DPP-IV Inhibitor Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number in Patients With Type 2 Diabetes in Metformin Failure
Brief Summary: The purpose of this study is to evaluate the effect of Dipeptidyl peptidase (DPP) -IV inhibitor Vildagliptin vs. Glibenclamide on circulating endothelial progenitor cells (EPCs) number in type 2 diabetes patients in metformin failure. Subjects will be followed for 12 months after randomization.


Options:
A: Arm Label: Vildagliptin & metformin; Type: EXPERIMENTAL; Interventions: Drug: Vildagliptin, Drug: Metformin | Arm Label: Glibenclamide & metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glibenclamide, Drug: Metformin | Intervention Type: DRUG; Name: Vildagliptin; Assigned to Arm(s): Vildagliptin & metformin | Intervention Type: DRUG; Name: Glibenclamide; Assigned to Arm(s): Glibenclamide & metformin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Glibenclamide & metformin, Vildagliptin & metformin
B: Arm Label: Lira 1.8; Type: EXPERIMENTAL; Interventions: Drug: liraglutide, Drug: placebo | Arm Label: Lira 1.2; Type: EXPERIMENTAL; Interventions: Drug: liraglutide, Drug: placebo | Arm Label: Glimepiride - 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: glimepiride, Drug: placebo | Arm Label: Glimepiride - 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: glimepiride, Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.8 | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): Glimepiride - 1, Glimepiride - 2 | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Lira 1.2, Lira 1.8 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Glimepiride - 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Glimepiride - 2
C: Arm Label: Dapagliflozin+metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dapagliflozin, Drug: Placebo for saxagliptin, Drug: Placebo for glimepiride | Arm Label: Dapagliflozin+saxagliptin+metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dapagliflozin, Drug: Saxagliptin, Drug: Placebo for glimepiride | Arm Label: Glimepiride+metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glimepiride, Drug: Placebo for dapagliflozin, Drug: Placebo for saxagliptin | Intervention Type: DRUG; Name: Dapagliflozin; Assigned to Arm(s): Dapagliflozin+metformin, Dapagliflozin+saxagliptin+metformin | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Dapagliflozin+saxagliptin+metformin | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Glimepiride+metformin | Intervention Type: DRUG; Name: Placebo for dapagliflozin; Assigned to Arm(s): Glimepiride+metformin | Intervention Type: DRUG; Name: Placebo for saxagliptin; Assigned to Arm(s): Dapagliflozin+metformin, Glimepiride+metformin | Intervention Type: DRUG; Name: Placebo for glimepiride; Assigned to Arm(s): Dapagliflozin+metformin, Dapagliflozin+saxagliptin+metformin
D: Intervention Type: DRUG; Name: muraglitazar; Assigned to Arm(s): N/A

Answer: A